Investor Relations

Corporate Profile

Autolus is a clinical-stage, biopharmaceutical company, focused on the development and commercialisation of engineered T-cell immunotherapy products to combat cancer. Utilising its advanced cell programming and manufacturing technologies, Autolus has a pipeline of products in development for the treatment of both haematological malignancies and solid tumours.

Press Releases


Nov 14 - Nov 15, 2018

Jefferies 2018 London Healthcare Conference

Dec 1 - Dec 4, 2018

American Society of Hematology (ASH)